The Synergistic Antitumor Effect of Arsenic Trioxide Combined with Cytotoxic T Cells in Pulmonary Metastasis Model of Colon Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jan 10

PMID 29312633

Citations 2

Authors

Lei Wang

Wentao Liang

Na Peng

Xiang Hu

Yingxin Xu

Zhong Liu

Affiliations

Soon will be listed here.

Abstract

Adoptive T cell therapy, including cytotoxic T lymphocytes (CTLs), represents a promising non-toxic anticancer strategy. The effects of this therapy can be impaired by tumor-infiltrated regulatory T cells (Tregs). Autologous murine CTLs acquired using cryopreservation exhibited a cytotoxic effect equivalent to that of conventional CTLs. The killing activity of CTLs was enhanced significantly using arsenic trioxide (ATO), accompanied by reduction in Tregs . Results using a pulmonary metastasis model of colon cancer indicated that compared with the control group, ATO group, and CTLs group, metastatic node number decreased significantly (<0.001, <0.001, <0.001, respectively) and survival time was prolonged (<0.001, =0.669, =0.158, respectively) in the ATO plus CTLs group. The number of infiltrated Foxp3+ Tregs decreased in the tumor center, but increased in the peri-tumor tissue. Our results indicate that this approach represents a practical protocol for acquiring autologous CTLs and a feasible strategy that uses a synergistic combination of ATO plus CTLs to treat pulmonary metastases of colon cancer.

Citing Articles

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy.

Zhang J, Wang L, Li S, Gao X, Liu Z Cancer Cell Int. 2022; 22(1):216.

PMID: 35715855 PMC: 9206283. DOI: 10.1186/s12935-022-02630-x.

Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.

Zhu G, Li X, Li J, Zhou W, Chen Z, Fan Y J Cancer. 2020; 11(22):6516-6529.

PMID: 33046973 PMC: 7545676. DOI: 10.7150/jca.47111.

References

Yan Y, Li S, Jia T, Du X, Xu Y, Zhao Y . Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 2015; 36(6):4535-43. DOI: 10.1007/s13277-015-3098-7. View

Dey-Hazra E, Hertel B, Kirsch T, Woywodt A, Lovric S, Haller H . Detection of circulating microparticles by flow cytometry: influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag. 2010; 6:1125-33. PMC: 3004516. DOI: 10.2147/VHRM.S13236. View

McCoy M, Hemmings C, Anyaegbu C, Austin S, Lee-Pullen T, Miller T . Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response. Oncotarget. 2017; 8(12):19803-19813. PMC: 5386723. DOI: 10.18632/oncotarget.15048. View

Yan G, Xi Y, Xu S, Lin Y, Chen J, Dai H . Inhibition of accelerated rejection mediated by alloreactive CD4⁺ memory T cells and prolonged allograft survival by arsenic trioxide. Immunol Invest. 2013; 42(5):438-54. DOI: 10.3109/08820139.2013.801986. View

Li K, Zhang L, Xiang X, Gong S, Ma L, Xu L . Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway. Ir J Med Sci. 2013; 182(4):573-83. DOI: 10.1007/s11845-013-0928-8. View

Vlad C, Kubelac P, Fetica B, Vlad D, Irimie A, Achimas-Cadariu P . The prognostic value of FOXP3+ T regulatory cells in colorectal cancer. J BUON. 2015; 20(1):114-9. View

Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q . Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol. 2015; 294(1):54-9. DOI: 10.1016/j.cellimm.2015.02.003. View

Thomas-Schoemann A, Batteux F, Mongaret C, Nicco C, Chereau C, Annereau M . Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer. J Immunol. 2012; 189(11):5171-7. DOI: 10.4049/jimmunol.1103094. View

Zhai B, Jiang X, He C, Zhao D, Ma L, Xu L . Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2014; 36(4):2323-34. DOI: 10.1007/s13277-014-2839-3. View

10.

Wang L, Peng N, Hu X, Liang W, Liang K, Peng G . [Acquirement of autologous murine cytotoxic T lymphocytes via cryopreservation of lymphocytes]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016; 32(11):1453-1457. View

11.

Luo Q, Li Y, Deng J, Zhang Z . PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair. Chem Biol Interact. 2014; 226:12-22. DOI: 10.1016/j.cbi.2014.12.007. View

12.

Lee J, Lee H, Moon C, Lee S, Lee W, Cha H . Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model. Transl Oncol. 2013; 6(1):83-91. PMC: 3573657. DOI: 10.1593/tlo.12322. View

13.

Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K . Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med. 2014; 7(7):1781-5. PMC: 4132144. View

14.

Li K, Zhang Q, Zhang Y, Yang J, Zheng J . T-cell-associated cellular immunotherapy for lung cancer. J Cancer Res Clin Oncol. 2014; 141(7):1249-58. DOI: 10.1007/s00432-014-1867-0. View

15.

Karimi S, Chattopadhyay S, Chakraborty N . Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy. Immunology. 2014; 144(2):186-96. PMC: 4298413. DOI: 10.1111/imm.12387. View

16.

Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson M . Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2012; 62(4):737-46. PMC: 3863727. DOI: 10.1007/s00262-012-1380-8. View

17.

Hinrichs C, Rosenberg S . Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2013; 257(1):56-71. PMC: 3920180. DOI: 10.1111/imr.12132. View

18.

Sharma A, Sharma R, Sharma S, Sharma A, Soni D . Typhoid intestinal perforation: 24 perforations in one patient. Ann Med Health Sci Res. 2013; 3(Suppl 1):S41-3. PMC: 3853607. DOI: 10.4103/2141-9248.121220. View

19.

Wang X, Jiang F, Mu J, Ye X, Si L, Ning S . Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491. Toxicol Lett. 2014; 227(2):75-83. DOI: 10.1016/j.toxlet.2014.03.016. View

20.

Li W, Wang M, Wang L, Ji S, Zhang J, Zhang C . Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochem Biophys. 2013; 68(2):427-36. DOI: 10.1007/s12013-013-9724-3. View